CVS Health's Stock Tumbles 14% in Premarket trading on Tuesday

7 авг.

CVS Health (NYSE: CVS) is grappling with significant challenges as its stock dropped 14% following the release of its second-quarter earnings report. Despite beating earnings expectations, the company has lowered its full-year profit outlook for the third consecutive quarter due to rising medical costs and operational shifts in its health insurance business.**

Earnings and Revenue Overview
CVS Health reported:
- Earnings per share (EPS): $1.83 (adjusted) vs. $1.73 expected by analysts
- Revenue: $91.23 billion vs. $91.5 billion expected

The company achieved a net income of $1.77 billion, or $1.41 per share, down from $1.90 billion, or $1.48 per share, in the same quarter last year. Revenue grew by 2.6% year-over-year, driven by its pharmacy and insurance businesses.

Profit Outlook and Executive Changes
CVS Health has revised its 2024 adjusted earnings outlook to $6.40-$6.65 per share, down from the previous guidance of at least $7 per share. This adjustment reflects ongoing pressure from higher medical costs, particularly within its health insurance segment, which includes Aetna's Medicare Advantage, Medicaid, and other plans.

In a significant management shift, Aetna President Brian Kane will leave the company immediately. CEO Karen Lynch will assume management responsibilities for the insurance unit, with CFO Thomas Cowhey and Chief Strategy Officer Katerina Guerraz assisting.

Medical Costs and Industry Pressures
The healthcare industry is experiencing increased medical costs as more Medicare Advantage patients return to hospitals for procedures delayed during the pandemic, such as joint and hip replacements. This trend is putting pressure on insurance companies like CVS Health, UnitedHealth Group, Humana, and Elevance Health.

CVS Health's Medicare Advantage star ratings, which help Medicare patients compare health and drug plans, have also impacted its performance. The company's medical benefit ratio rose to 89.6% from 86.2% a year earlier, indicating higher medical expenses relative to premiums collected.

Segment Performance
- Insurance Segment: Generated $32.48 billion in revenue, up 21% year-over-year, but reported adjusted operating income of $938 million, below analyst expectations.
- Health Services Segment: Generated $42.17 billion in revenue, down nearly 9% year-over-year. Processed 471.2 million pharmacy claims, down from 576.6 million a year ago.
- Pharmacy and Consumer Wellness Division: Reported $29.84 billion in sales, up over 3% year-over-year, driven by increased prescription volume.

However, the segment faced challenges from pharmacy reimbursement pressure, the introduction of new generic drugs, and decreased front-store volume.

Strategic Adjustments
CVS Health's pharmacy benefit manager (PBM) Caremark has seen declines due to losing key clients like Tyson Foods and Blue Shield of California. These losses reflect broader industry shifts towards transparency and cost reduction, with startups and government initiatives reshaping the landscape.

Conclusion
CVS Health's third-quarter earnings report underscores the significant challenges facing the company as it navigates rising medical costs and shifting industry dynamics. The lowered profit outlook and executive changes signal the need for strategic adjustments to address these pressures. As CVS Health adapts to these evolving conditions, the market will closely watch its efforts to stabilize and grow its diverse healthcare and retail operations.